{
    "clinical_study": {
        "@rank": "104059", 
        "acronym": "RENEW", 
        "arm_group": [
            {
                "arm_group_label": "BIIB033", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses)."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the efficacy of BIIB033 in subjects with\n      their first episode of unilateral Acute Optic Neuritis (AON).  The secondary objective of\n      this study in this study population is to assess the safety, tolerability, and\n      pharmacokinetics (PK) of BIIB033."
        }, 
        "brief_title": "215ON201 BIIB033 In Acute Optic Neuritis (AON)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Optic Neuritis", 
        "condition_browse": {
            "mesh_term": [
                "Neuritis", 
                "Optic Neuritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Ability to provide written consent and any authorization required by law.\n\n          -  Confirmed diagnosis of Acute Optic Neuritis (AON)\n\n          -  All male or female subjects of childbearing potential must practice effective\n             contraception during the study and be willing and able to continue contraception for\n             at least 6 months after their last dose of study treatment.\n\n        Key Exclusion Criteria:\n\n          -  Prior episode(s) of optic neuritis or loss of vision not due to AON.\n\n          -  Subjects with an established diagnosis of Multiple Sclerosis are excluded except if\n             newly diagnosed based on the current episode of AON and positive brain MRI results\n             consistent with the 2010 revisions to the McDonald's criteria.\n\n          -  Previous history of a clinically significant disease.\n\n          -  Females who have a positive pregnancy test result, or who are pregnant,\n             breastfeeding, or planning to conceive during the study.\n\n          -  History of human immunodeficiency virus (HIV), hepatitis C virus antibody, or\n             hepatitis B virus.\n\n          -  History or evidence of drug or alcohol abuse within 2 years prior to Screening.\n\n          -  Current enrollment in any other study treatment or disease study within 3 months\n             prior to Day 1/Baseline.\n\n        NOTE: Other protocol defined criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721161", 
            "org_study_id": "215ON201"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIIB033", 
                "description": "100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).", 
                "intervention_name": "BIIB033", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Optic Neuritis", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ghent", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limberg", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glostrup", 
                        "country": "Denmark"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bamberg", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dusseldorf", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany"
                    }, 
                    "name": "Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tubingen", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fidenza", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Research site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cordoba", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palmar", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Spain", 
                "Sweden", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis", 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Spain: Spanish Agency for Medicines and Health Products", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Italy: The Italian Medicines Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Sweden: Medical Products Agency", 
                "Hungary: National Institute of Pharmacy", 
                "Canada: Health Canada", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in optic nerve conduction velocity (NCV) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by full-field visual evoked potential (FF-VEP).", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in thickness of the retinal nerve fiber layer (RNFL) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by spectral-domain optical coherence tomography (SD-OCT).", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Change in thicknesses of the retinal ganglion cell layer/inner plexiform retinal layer (RGCL/IPL) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by segmentation of SD-OCT.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Change in low-contrast letter acuity (LCLA) at Week 24 from baseline as determined by 1.25% and 2.5% low contrast Sloan letter charts.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of participants with Adverse events (AEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "32 weeks"
            }, 
            {
                "description": "One pre-dose PK sample and 1 post-dose PK sample (approximately between 1 and 3 hours after the end of IV infusion) will be collected for ALL participants on Day 1 and at Weeks 4 through 20 (every 4 weeks). Additionally, only 1 PK sample will be collected at Week 24 and Week 32.", 
                "measure": "PK Parameters will be estimated based on Population based PK modeling.", 
                "safety_issue": "No", 
                "time_frame": "Up to 32 weeks"
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "collaborator": {
                "agency": "Biogen Idec Australia Pty Ltd", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}